Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28855427 | 0.79 | GRM5 (0.49) | GRM5CTSVCTSLALDH1A1RAB9A | |
| SCHEMBL29901110 | 0.79 | GRM5 (0.49) | GRM5CTSVCTSLALDH1A1RAB9A | |
| SCHEMBL1663438 | 0.79 | MEN1 (0.57) | CTSVCTSLRAB9AMEN1NPC1 | |
| SCHEMBL30832846 | 0.79 | MEN1 (0.57) | CTSVCTSLRAB9AMEN1NPC1 | |
| Potassium Ion SCHEMBL10618645 | 0.78 | MEN1 (0.53) | CTSVCTSLRAB9AMEN1NPC1 | |
| SCHEMBL15819302 | 0.76 | HTR1A (0.53) | CTSVCTSLALDH1A1RAB9AMEN1 | |
| SCHEMBL29502844 | 0.76 | POLB (0.58) | CTSVCTSLPOLBRAB9AMEN1 | |
| SCHEMBL5579665 | 0.76 | ESR1 (0.83) | ESR1ESR2ALDH1A1POLBMEN1 | |
| SCHEMBL5421861 | 0.76 | POLB (0.58) | CTSVCTSLPOLBRAB9AMEN1 | |
| SCHEMBL1163442 | 0.75 | MAOB (0.54) | CTSVCTSLRAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | GRM5 366/4885ESR1 6/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.